“AstraZeneca” said that this drug, which is made of a mixture of antibodies, provides 83 percent protection, for a period of 6 months..
And the drug, called (AZD7442) or “EvoShield”, had previously achieved 77 percent protection in cases of symptomatic infection after 3 months, according to a previous reading of the results of a late-stage trial confirmed in August.
The company also stated that a separate study on patients with symptoms ranging from moderate to mild for “Covid-19”, revealed that taking a higher dose of the drug prevents the deterioration of symptoms by 88 percent, if the patient receives treatment within 3 days of the appearance of the first symptoms.
The patient receives the drug once in two injections. EvoShield belongs to a class of drugs based on monoclonal antibodies, which are proteins that are made in the laboratory and that mimic the natural defenses of the human body..
It is based on the antibodies that the body produces in case of infection or vaccination, according to Reuters.
.